Arbutus Biopharma Corporation (NASDAQ: ABUS) announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit SuisseSeptember 21, 2017 6:26 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP SecuritiesSeptember 20, 2017 2:14 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at StifelSeptember 20, 2017 1:41 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'September 20, 2017 12:36 PM Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran ProgramSeptember 20, 2017 12:22 PM Royalty Stream to Arbutus Biopharma (ABUS) from Alnylam (ALNY) 'Could be Significant' - WedbushSeptember 20, 2017 10:19 AM Arbutus Biopharma (ABUS) Gains Sharply Following Alnylam Trial SuccessSeptember 20, 2017 10:12 AM